<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454584</url>
  </required_header>
  <id_info>
    <org_study_id>CR013015</org_study_id>
    <secondary_id>C0743T12</secondary_id>
    <secondary_id>2006-003444-30</secondary_id>
    <nct_id>NCT00454584</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in
      patients with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized (study medication assigned by chance), active-controlled,
      parallel, 3-arm study. Patients will be randomly (allocation to treatments available by
      chance) assigned in 3:5:5 ratio to receive one of three treatments groups. The three
      treatment groups are: Group 1 - CNTO 1275 45 mg dosing at weeks 0 and 4, Group 2 - CNTO 1275
      90 mg dosing at weeks 0 and 4, Group 3 - Etanercept 50 mg two times per week through week 12.
      The total duration for each participant will be up to 64 weeks (approximately 16 months). The
      active-controlled portion of the study is from Week 0 to Week 12 during which the efficacy
      and safety of etanercept and 2 dose levels of CNTO 1275 will be evaluated. Treatment after
      Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial
      treatment assignment. Patients will receive 2 subcutaneous injections of CNTO 1275 (either 45
      or 90 mg doses) or twice weekly injections of etanercept during the first twelve weeks of the
      study. Patients may receive two additional doses of CNTO 1275 (either 45 or 90 mg doses) up
      to week 44.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Number of participants achieving greater than or equal to 75 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst). Baseline visit refers to Week 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Physician's Global Assessment (PGA) of Cleared or Minimal at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of participants achieving a physician global assessment (PGA) (0-5) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trial of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Greater Than or Equal to 90 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 90) Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Number of participants achieving greater than or equal to 90 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Psoriasis Area Severity Index Between Week 12 and That Achieved 12 Weeks After Retreatment (Week R12)</measure>
    <time_frame>Up to Week 52. Retreatment may occur anytime between Week 16 and Week 40 depending on time of losing PGA response. Hence end of 12 weeks of retreatment would be between Week 28 and Week 52, inclusive.</time_frame>
    <description>The difference between the PASI score at Week 12 and that achieved after 12 weeks of retreatment. The PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">903</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>CNTO 1275 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNTO 1275 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 1275 45 mg</intervention_name>
    <description>Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous</description>
    <arm_group_label>CNTO 1275 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 1275 90 mg</intervention_name>
    <description>Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous</description>
    <arm_group_label>CNTO 1275 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept 50 mg</intervention_name>
    <description>Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous</description>
    <arm_group_label>Etanercept 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the study

          -  Have plaque-type psoriasis covering at least 10 percentage of total body surface area

          -  Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater and a
             Physician's Global Assessment (PGA) score of 3 or greater at the time of the first
             administration of study drug

          -  Must be suitable for phototherapy or systemic treatment for psoriasis

          -  Have failed to respond to or have condition which prevents use of cyclosporine,
             methotrexate (MTX) or psoralen plus ultraviolet light A (PUVA)

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis

          -  Have current drug-induced psoriasis

          -  Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or IL-23
             (Interleukins are the substance produced by body in immunological disease like
             psoriasis)

          -  Have received phototherapy or any systemic medications/treatments that could affect
             psoriasis or PASI evaluation (including, but not limited to, oral or injectable
             corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, psoralens,
             sulfasalazine, hydroxyurea, or fumaric acid derivatives) within 4 weeks of the first
             administration of study agent

          -  Have used a biologic within the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <results_first_submitted>October 23, 2009</results_first_submitted>
  <results_first_submitted_qc>October 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2012</results_first_posted>
  <last_update_submitted>October 19, 2012</last_update_submitted>
  <last_update_submitted_qc>October 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>CNTO 1275</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Immune diorder</keyword>
  <keyword>Skin disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>903 partcipants received either ustekinumab (CNTO 1275) or etanercept at 67 sites in North America and Europe.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept (CP)</title>
          <description>Controlled period (Week 0-12) - Etanercept group</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="P4">
          <title>Etanercept (After CP)</title>
          <description>After Controlled period (Week 12- 64) – receiving etanercept at Weeks 0 -&gt; receiving ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40</description>
        </group>
        <group group_id="P5">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving ustekinumab 45 mg at Weeks 0 -&gt; retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.</description>
        </group>
        <group group_id="P6">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving ustekinumab 90 mg at Weeks 0 -&gt; retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="347"/>
                <participants group_id="P4" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
                <participants group_id="P5" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
                <participants group_id="P6" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="336"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="342"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P4" count="336"/>
                <participants group_id="P5" count="201"/>
                <participants group_id="P6" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="310"/>
                <participants group_id="P5" count="189"/>
                <participants group_id="P6" count="310"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I: Etanercept</title>
          <description>Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
        </group>
        <group group_id="B2">
          <title>Group II: Ustekinumab 45 mg</title>
          <description>Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
        </group>
        <group group_id="B3">
          <title>Group III: Ustekinumab 90 mg</title>
          <description>Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="347"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="347"/>
            <count group_id="B4" value="903"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="13.40"/>
                    <measurement group_id="B2" value="45.1" spread="12.56"/>
                    <measurement group_id="B3" value="44.8" spread="12.29"/>
                    <measurement group_id="B4" value="45.2" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12</title>
        <description>Number of participants achieving greater than or equal to 75 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst). Baseline visit refers to Week 0.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participants is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or has missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Etanercept</title>
            <description>Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12</title>
          <description>Number of participants achieving greater than or equal to 75 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst). Baseline visit refers to Week 0.</description>
          <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participants is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or has missing data at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and etanercept at an overall significant level of 0.05. Sample Size: Assuming the PASI 75 response rates of ustekinumab 90 mg, 45 mg, etanercept are 65%, 64%, and 50% , respectively, with 325 participants each in the ustekinumab 90 mg and etanercept groups, the power to detect a treatment difference is 97%. With 200 participants in the ustekinumab 45 mg group, the complete power to further detect a treatment difference was 87%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>To control the overall type I error rate at 0.05 level in the primary endpoint analysis, a step-down test procedure was applied. First, ustekinumab 90 mg and etanercept were compared. Then ustekinumab 45 mg and etanercept would be compared.</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Physician's Global Assessment (PGA) of Cleared or Minimal at Week 12</title>
        <description>Number of participants achieving a physician global assessment (PGA) (0-5) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trial of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had a missing PGA score.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Etanercept</title>
            <description>Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physician's Global Assessment (PGA) of Cleared or Minimal at Week 12</title>
          <description>Number of participants achieving a physician global assessment (PGA) (0-5) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trial of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
          <population>Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had a missing PGA score.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and etanercept at an overall significant level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Greater Than or Equal to 90 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 90) Score at Week 12</title>
        <description>Number of participants achieving greater than or equal to 90 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. A participant is considered a non-responder if the participant has used any pre-specified prohibited medications, discontinued due to lack of efficacy, or had a missing Week 12 PASI score.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Etanercept</title>
            <description>Participants received Etanercept 50 mg twice weekly through Week 12. Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16 and 20. Participants with PGA leeser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Greater Than or Equal to 90 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 90) Score at Week 12</title>
          <description>Number of participants achieving greater than or equal to 90 percentage improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12. PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
          <population>Intent to treat. All randomly assigned participants were included in the analysis according to the assigned treatment groups. A participant is considered a non-responder if the participant has used any pre-specified prohibited medications, discontinued due to lack of efficacy, or had a missing Week 12 PASI score.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and etanercept at an overall significant level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>The test was stratified by baseline weight [&lt;90kg vs. ≥ 90 kg).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Psoriasis Area Severity Index Between Week 12 and That Achieved 12 Weeks After Retreatment (Week R12)</title>
        <description>The difference between the PASI score at Week 12 and that achieved after 12 weeks of retreatment. The PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
        <time_frame>Up to Week 52. Retreatment may occur anytime between Week 16 and Week 40 depending on time of losing PGA response. Hence end of 12 weeks of retreatment would be between Week 28 and Week 52, inclusive.</time_frame>
        <population>Participants who were randomized to ustekinumab, had a PGA score less than or equal to 2 at Week 12, and were retreated upon losing PGA response (PGA greater than or equal to 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 45 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 45 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
          <group group_id="O2">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4 . Participants with PGA greater than or equal to 3 at Week 12 received ustekinumab 90 mg at Week 16. Participants with PGA lesser than or equal to 2 at Week 12 received ustekinumab 90 mg upon losing PGA response (PGA greater than or equal to 3) and 4 weeks after.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Psoriasis Area Severity Index Between Week 12 and That Achieved 12 Weeks After Retreatment (Week R12)</title>
          <description>The difference between the PASI score at Week 12 and that achieved after 12 weeks of retreatment. The PASI is the widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score. The scale ranges from 0 (best) -72 (worst).</description>
          <population>Participants who were randomized to ustekinumab, had a PGA score less than or equal to 2 at Week 12, and were retreated upon losing PGA response (PGA greater than or equal to 3).</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="3.799"/>
                    <measurement group_id="O2" value="-0.30" spread="4.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 64</time_frame>
      <desc>One participant in Etanercept (after controlled period [CP]), 1 participant in Ustekinumab 90 mg (after CP) and 3 participants stekinumab 45 mg (after CP) arms were discontinued study agent during the CP but had follow-up after CP and hence were included in the tables of frequent adverse events and serious adverse events after CP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etanercept (CP)</title>
          <description>Controlled period (Week 0-12) - Etanercept group</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="E4">
          <title>Etanercept (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving etanercept at Weeks 0 -&gt; prior to being treated with ustekinumab</description>
        </group>
        <group group_id="E5">
          <title>Etanercept -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving etanercept at Weeks 0 -&gt; receiving ustekinumab 90 mg upon becoming a nonresponder during Week 12 and Week 40. This group is a subpopulation of Etanercept (after CP).</description>
        </group>
        <group group_id="E6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving ustekinumab 45 mg at Weeks 0 -&gt; retreated with ustekinumab 45 mg if becoming a nonresponder during Week 12 and Week 40.</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-64) – receiving ustekinumab 90 mg at Weeks 0 -&gt; retreated with ustekinumab 90 mg if becoming a nonresponder during Week 12 and Week 40.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Uvulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="102" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="85" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="164" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Compound Development Team Leader</name_or_title>
      <organization>Centocor Research &amp; Development, Inc.</organization>
      <phone>1 215-793-7612</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

